SymbioCellTech has Patents filed in the U.S., Canada, Europe, Australia, New Zealand and Japan. Inventors C. Westenfelder, A. Gooch, et al.

  • Neo-Islets comprising stem and islet cells and treatment of Diabetes Mellitus therewith

  • Adaptation of hollow-fiber-based cell culture technology for the manufacturing of:
    (1) Neo-Islets, employed for the treatment of Type 1 and Type 2 Diabetes Mellitus, and
    (2) the generation of Exosomes from various cell types, used in the treatment of different organ injuries and diseases

  • Treatment of microvascular disorders with Mesenchymal Stem Cells and their Exosomes

  • Cell clusters comprising stem and islet cells, methods of making, and treatment of Diabetes Mellitus therewith

  • Species-specific tissue culture medium for the propagation of mammalian cells

IP Strategy:

SymbioCellTech Trade Secrets include technologies and know-how relating to the preparation, culture, storage, and engineering of “Neo-Islets,” continuously evaluated for additional patentability.

New SymbioCellTech technologies (e.g., highly efficient and cost-saving Culture Expansion of Insulin producing cells) are evaluated for strategic value and patentability on an ongoing basis.